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Abstract Studies have shown that beta defensins are present in
the human airways and may be relevant to the pathogenesis of
cystic fibrosis lung disease. Here we report the identification of a
novel mouse gene, Defb2, which shows sequence similarity to
previously described mouse and human airway beta defensins.
Defb2 does not appear to be expressed in the airways of
untreated mice but it is upregulated in response to lipopolysac-
charide. The induced expression of this gene by an inflammatory
stimulus strongly suggests that this defensin contributes to host
defence at the mucosal surface of the airways.
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1. Introduction
Defensins are a large family of antimicrobial cationic pep-
tides of which two groups are present in vertebrates (alpha
and beta) distinguishable by the spacing and connectivity of
the conserved cysteine residues within the mature peptide.
Recent studies have shown beta defensins to be present in
the airway epithelia of several species including humans, ro-
dents and cattle where they contribute to the host defence
system by the eradication of pathogens at the mucosal sur-
face. There have been two beta defensins identi¢ed in humans
to date, hBD-1 and hBD-2 [1^3]. HBD-1 synthetic peptides
have been shown to have a broad spectrum bactericidal activ-
ity which is markedly reduced in elevated salt concentrations
similar to those reported for cystic ¢brosis (CF) airway sur-
face £uid (ASF) [1,4,5]. HBD-2 has also been shown to have a
salt-sensitive antimicrobial activity [6] and similar to the bo-
vine beta defensin, TAP, but unlike hBD-1, can be transcrip-
tionally induced by bacterial products [3]. It was therefore
proposed that the reduced ability of these beta defensins to
kill bacteria in the CF environment was of relevance to the
pathogenesis of CF lung disease and gave some form of ex-
planation for the early onset of bacterial colonisation in the
CF lung [1]. We recently reported the identi¢cation and char-
acterisation of a mouse beta defensin, Defb1, whose protein
sequence had 57% similarity to HBD-1, was expressed in the
airway epithelia and whose synthetic peptide was shown to
have salt-sensitive antimicrobial activity [4]. Here we report
the identi¢cation of a second mouse beta defensin, Defb2,
from a BAC containing Defb1. We show that its expression,
unlike hBD-1 or Defb1 but in common with hBD-2, is induced
in the airways by lipopolysaccharide (LPS). This supports the
hypothesis that beta defensins contribute to a dynamic host
defence at the mucosal surfaces.
2. Materials and methods
2.1. Isolation of mouse defensin-related gene
Defb1 is located on BACs I8 and I20 (Research Genetics Inc.) and
these were screened for the presence of related defensin genes by
Southern hybridisation using the Defb1 cDNA sequence as the probe
at a reduced stringency hybridisation temperature of 55‡C. A 2 kb
fragment of BAC DNA was subcloned which only hybridised to the
Defb1 probe at the reduced stringency temperature, indicating it was
not Defb1.
2.2. DNA sequencing
Puri¢ed plasmid DNA was sequenced from both strands using ABI
Prism dRhodamine Terminator Cycle Sequencing Ready Reaction Kit
(PE Applied Biosystems).
2.3. RACE
Total RNA was prepared from C57BL/6N adult mouse kidney
tissue using RNAzol B (Biogenesis) as described by the manufacturer.
First strand cDNA synthesis was performed using SuperscriptII (Gib-
co BRL) and primer R1 (CATTTCATGTACTTGCAACAG). Prod-
ucts were size selected by microdialysis on a 0.025 WM ¢lter against
TE for 4 h and then poly-A tailed. Second strand cDNA synthesis
was accomplished using primer R2 (CCTGCTCGAATTCAAGCTT-
CTTTTTTTTTTTTTTTTT) and the products microdialysed on a
0.1 WM ¢lter against TE for 4 h. PCR ampli¢cation of the resultant
cDNAs was performed using primers R3 (CCAGGACGCCTGACA-
GAAGG) and R4 (CCTGCTCGAATTCAAGCTTC) and the follow-
ing conditions: 30 cycles of 94‡C for 1.5 min, 60‡C for 1.5 min and
72‡C for 3 min. Products were then microdialysed on a 0.1 Wm ¢lter
against TE for 4 h and a nested PCR performed using primer R4 and
R5 (CCCTCCATTGGTGTGGCAGTG) with cycling conditions as
above. PCR products were analysed on a 1% agarose gel by electro-
phoresis and cloned using Original TA Cloning Kit (Invitrogen).
Cloned products were analysed by hybridisation with an exon-speci¢c
oligo (GGATACGAAGCAGAAC) and an intron-speci¢c oligo
(CGAGACAATTGCTTGG). Clones positive for the exon-speci¢c
oligo and not the intron-speci¢c oligo were sequenced as above.
2.4. Long-range PCR
Long-range PCR was performed on 50 ng BAC I8 or 1 Wg genomic
DNA using the Extend Long Template PCR System (Boehringer
Mannheim) and primers dr1 (GCCATGAGGACTCTCTGCTC)
and dr2 (TGTCACTTGACTTCCATGTGC) and the following con-
ditions: denaturation 92‡C for 2 min; 30 cycles 92‡C for 10 s, 65‡C
for 30 s and 68‡C for 15 min; ¢nal extension 68‡C for 7 min. The
ampli¢ed products were analysed on a 0.7% agarose gel by electro-
phoresis. The gels were then blotted and probed with an internal oligo
(R5).
2.5. Tissue expression of Defb2
Total RNA was isolated from a variety of tissues from C57BL/6N
mice using RNAzol B as described by the manufacturer. The samples
were DNase-treated then cDNA synthesis was accomplished using a
¢rst strand cDNA synthesis kit (Boehringer Mannheim). The resultant
cDNAs were used as a template in a PCR reaction for Defb2 with
primers dr1 and dr2 and the following conditions: 30 cycles of 94‡C
for 30 s, 56‡C for 30 s and 72‡C for 1 min. The ampli¢ed products
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(250 bp) were then analysed on a 2% agarose gel by electrophoresis.
Ampli¢cation of Hprt was carried out in parallel as previously de-
scribed [4]. Reactions were veri¢ed for RNA ampli¢cation by includ-
ing controls without reverse transcriptase.
2.6. LPS administration and semi-quantitative RT-PCR
40 Wg of LPS (Escherichia coli O55:B5, Sigma) was administered to
mice by intratracheal delivery and the mice were killed at various
timepoints after instillation. Total RNA was isolated from the lungs
and trachea and RT-PCR for Defb2 was performed as described
above.
2.7. Quanti¢cation of tumour necrosis factor-K (TNF-K)
C57BL/6N mice were treated with 40 Wg of LPS as described above.
The mice were killed 1, 2, 4, 24 or 48 h after treatment and their lungs
lavaged with 3U1 ml sterile PBS. Undiluted lavage £uid and a 1:10
dilution were assayed in duplicate for murine TNF-K using a com-
mercially available ELISA kit (Genzyme).
2.8. Culture of primary mouse epithelial cells
Tracheal epithelial cells were isolated from eight male C57BL/6N
mice, seeded onto four collagen-coated, cell culture inserts (Costar
Transwell-Clear 3470, 0.4 Wm pore size, 0.5 mm diameter) and grown
with an air-liquid interface to con£uent, polarised, ciliated monolayer
as described (Davidson et al., in preparation).
2.9. LPS administration to primary mouse epithelial cells
Primary cultures were used 12 days after seeding, adding 80 Wg of
LPS (E. coli O55:B5, Sigma) in 25 Wl of PBS to the apical surface of
the primary culture or 25 Wl of PBS alone on the controls. The cells
were incubated at 37‡C for 4 h then washed three times with PBS
before isolation of RNA.
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Fig. 1. Diagrammatic representation of mouse chromosome 8 indi-
cating the relative positions of Defb2, Defb1 and the alpha (K) de-
fensin gene cluster.
Fig. 2. A: Comparison of Defb2 and Defb1 nucleotide sequence. Start codon, stop codon and poly-A signal are highlighted in bold. s indicates
the boundary between exon 1 and exon 2. B: Comparison of the predicted amino acid sequences of Defb2 and Defb1. Vertical line, direct
match; two dots, close similarity; one dot, some similarity. C: Peptide similarities between the mouse beta defensins Defb1 and Defb2 and the
human beta defensins HBD1 and HBD2.
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3. Results
3.1. Identi¢cation of a novel mouse sequence related to Defb1
Defb1 had previously been located on BACs I8 and I20 [4]
and following low-stringency hybridisation, with Defb1 cDNA
as a probe, several novel bands were observed for BAC I8. No
novel bands were observed for BAC I20. Since BAC I20 has
been found to contain murine alpha defensin sequences [4] it
indicated that these novel bands came from sequences more
distal to the alpha defensin gene cluster than Defb1 (see
Fig. 1). A 2 kb hybridising fragment from BAC I8 was cloned
and sequenced and a region of the sequence was shown to
have homology to exon 2 of Defb1. An exon/intron predictor
program indicated an intron/exon boundary site for the
new sequence in the same position as that of Defb1. Therefore
the 2 kb cloned region from BAC I8 was shown to contain a
region showing homology to exon 2 of Defb1 and also 1.5 kb
of an intronic region 5P to the putative exon 2. The 5P end of
the cDNA was successfully cloned by RACE and this novel
gene was named Defb2 (EMBL accession number AJ011800).
Its nucleotide sequence was shown to be 60% identical to
Defb1 and the peptide translation of the entire coding se-
quence was found to have 50% similarity to Defb1 (see Fig.
2A,B). Fig. 2C shows the similarity of this predicted peptide
to Defb1 and the human beta defensins HBD1 and HBD2.
Long-range PCR, shown in Fig. 3A, con¢rmed the presence
of an intron of 4 kb between exons 1 and 2 and Fig. 3B is a
restriction map of Defb2 which was found to extend over
approximately 5 kb of genomic DNA.
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Fig. 3. A: PCR across the Defb2 intron using BAC I8 or mouse to-
tal genomic DNA. 1, 2 and 3 refer to the bu¡ers used in the PCR
reactions containing 17.5 mM MgCl2, 22.5 mM MgCl2 or 22.5 mM
MgCl2 and detergents, respectively. Defb2 PCR products were veri-
¢ed by hybridisation to a Defb2 internal probe. B: Restriction map
of Defb2.
Fig. 4. RT-PCR of Hprt and Defb2 from various mouse tissue
RNAs. A plus (+) and minus (3) reverse transcriptase reaction is
shown for each sample. Defb2 PCR products were veri¢ed by hy-
bridisation to a Defb2 internal probe.
Fig. 5. A: RT-PCR of Hprt and Defb2 from tracheal RNA following LPS instillation. The hours shown represent the time after LPS instilla-
tion when the mice were killed with a plus (+) and minus (3) reverse transcriptase reaction shown for each sample. B: RT-PCR of Hprt and
Defb2 from mouse primary epithelial cells in the absence of LPS and 4 h following LPS instillation. Defb2 PCR products were veri¢ed by hy-
bridisation to a Defb2 internal probe.
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3.2. Expression of Defb2
Fig. 4 shows expression of Defb2 by RT-PCR was detected
in kidney and uterus and at much lower levels in the heart.
RT-PCR failed to detect any Defb2 expression in any other
tissue tested. We examined the airways in response to LPS
administration and found Defb2 expression to be induced in
the trachea (see Fig. 5A).
Expression of Defb2 was not found in primary cultures of
mouse tracheal epithelium under normal conditions but its
expression was found to be induced to a detectable level 4 h
after LPS administration to the cells as shown in Fig. 5B.
3.3. TNF-K expression following LPS treatment
Fig. 6 shows TNF-K levels to be increased in the mouse
airways in response to LPS treatment. The maximum level
of TNF-K was found to be approximately 100-fold higher
than normal levels and was detected 2 h after LPS adminis-
tration.
4. Discussion
The amino acid sequence, chromosomal localisation and
expression data of Defb2 indicate it to be a member of the
murine beta defensin family. We have previously demon-
strated the close physical proximity of the alpha defensin
gene cluster to Defb1 on mouse chromosome 8 [4] and here
we have identi¢ed a second mouse beta defensin within the
same BAC indicating that the two mouse beta defensins are
also in close proximity.
It is likely that gene duplication of a common ancestral
defensin gene occurred before man/mouse species divergence
to create the alpha and beta defensin genes [7]. The di¡erences
between the mouse and human alpha defensins indicates that
this branch of the defensin family expanded after man/mouse
species divergence. The nucleotide sequence identity of 60%
between Defb1 and Defb2 suggests that these two genes di-
verged from each other a long time ago, possibly before mam-
malian radiation. However, further studies on the evolution of
these genes are required before any predictions can be made
on when beta defensin gene expansion occurred in these two
species. Defb2 does appear to be homologous to the two hu-
man beta defensins found to date but due to the dissimilarity
in nucleotide sequence to these human genes it is unlikely that
Defb2 is the orthologue of hBD-1 or hBD-2. However, it is
possible that an, as yet undiscovered, human beta defensin
exists which is more similar to Defb2 and work is currently
under way to explore this possibility. It is hoped that the
identi¢cation of additional members of the defensin family
in mouse and man, if they exist, will help to clarify the evo-
lution of these peptides. To date, this is only the second mur-
ine beta defensin identi¢ed that is expressed in the airways.
The fact that its expression, unlike Defb1, was not found to be
constitutive in the lung but that it is induced following an
in£ammatory stimulus suggests that this defensin may be an
important component of the host response to pathogens. Ex-
pression was detectable from primary mouse epithelial cells 4 h
after LPS administration whereas Defb2 expression was not
detected from tracheal tissue until 24 h after LPS treatment.
The di¡erence in the kinetics of the Defb2 response may sim-
ply be a re£ection of the di¡erent experimental conditions
employed or it may indicate that non-epithelial cells found
in the trachea may have a role in the regulation of Defb2
expression.
Functional studies have not been performed on this novel
defensin but, due to its predicted structural similarities to the
other defensins with conserved cysteine domains capable of
forming disulphide bridges, it is anticipated that it will be
antimicrobial. The mechanisms which lead to the upregulation
of Defb2 in response to LPS are unknown. Studies on the
bovine airway beta defensin TAP have revealed the presence
of the nuclear transcription factors NF-UB and NF-IL6 bind-
ing sites in the 5P untranslated region (UTR) of the gene [8]
o¡ering a possible explanation as to inducible gene expression
via interactions with these cis-acting sequences. It will be of
interest to investigate whether there are any similar regulatory
control elements present in the 5P UTR or the promoter re-
gion of Defb2. It has also been shown that TAP expression
can be induced by the addition of the pro-in£ammatory cyto-
kine TNF-K and we have demonstrated in the mouse that
treatment with LPS also leads to an induction of TNF-K ex-
pression in the airways. TNF-K mediates its downstream sig-
nals via NF-UB and therefore the actions of raised levels of
TNF-K may cause the upregulation of Defb2. TAP expression
has also been shown to involve the actions of the LPS binding
protein CD14 [9]. CD14 is known to be released from mouse
bronchial epithelial cells [10] and therefore it is also possible
that it is also involved in the induction of Defb2.
The RT-PCR analysis performed was at best semi-quanti-
tative but indicated that Defb2 is expressed at a low level. It is
possible that the Defb2 peptide may only be required at low
levels to have a potent antimicrobial activity or that it has
synergistic e¡ects with other beta defensins in the mouse air-
ways or with other antimicrobial substances such as lysozyme.
In conclusion, we have identi¢ed a novel mouse beta defen-
sin whose expression is upregulated in the airways in response
to an in£ammatory stimulus. Studies are currently ongoing to
elucidate the antimicrobial actions of this peptide, whether its
activity is salt-sensitive and the e¡ects of di¡erent pathogens
on the inducibility of this gene in the airways. It will also be
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Fig. 6. Levels of TNF-K retrieved from mouse airways following
LPS instillation. Each timepoint represents the mean TNF-K value
of ¢ve mice. Standard deviation bars have been applied to all the
mean values.
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interesting to examine whether this defensin has any synergis-
tic e¡ects with other mouse beta defensins or antimicrobial
substances.
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